• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    4/19/24 8:08:38 AM ET
    $CHRO
    $ERAS
    $HLTH
    $INBS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CHRO alert in real time by email

    Gainers

    • Chromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million.
    • Kineta (NASDAQ:KA) stock moved upwards by 16.62% to $0.57. The market value of their outstanding shares is at $6.2 million.
    • Portage Biotech (NASDAQ:PRTG) shares moved upwards by 14.83% to $0.28. The company's market cap stands at $5.4 million.
    • Erasca (NASDAQ:ERAS) stock rose 13.73% to $2.04. The company's market cap stands at $308.4 million.
    • MSP Recovery (NASDAQ:LIFW) shares moved upwards by 13.25% to $0.94. The company's market cap stands at $14.9 million. As per the press release, Q4 earnings came out 4 days ago.
    • Cue Health (NASDAQ:HLTH) stock moved upwards by 12.25% to $0.16. The market value of their outstanding shares is at $25.2 million.

    Losers

    • Nexalin Technology (NASDAQ:NXL) stock fell 18.4% to $1.2 during Friday's pre-market session. The company's market cap stands at $8.9 million.
    • iSpecimen (NASDAQ:ISPC) stock decreased by 13.31% to $0.36. The market value of their outstanding shares is at $3.3 million.
    • INVO Bioscience (NASDAQ:INVO) stock decreased by 11.85% to $1.34. The company's market cap stands at $3.6 million. As per the news, the Q4 earnings report came out 3 days ago.
    • Intelligent Bio Solutions (NASDAQ:INBS) stock fell 10.72% to $2.5. The company's market cap stands at $7.1 million.
    • Trevena (NASDAQ:TRVN) stock decreased by 10.39% to $0.33. The company's market cap stands at $6.0 million.
    • PaxMedica (NASDAQ:PXMD) stock fell 9.58% to $0.69. The market value of their outstanding shares is at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CHRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHRO
    $ERAS
    $HLTH
    $INBS

    CompanyDatePrice TargetRatingAnalyst
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    Erasca Inc.
    $ERAS
    1/7/2026$5.00Overweight
    Piper Sandler
    Erasca Inc.
    $ERAS
    10/16/2025$4.00Buy
    Stifel
    Erasca Inc.
    $ERAS
    9/3/2025Buy → Underperform
    BofA Securities
    Erasca Inc.
    $ERAS
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    Erasca Inc.
    $ERAS
    3/26/2025$5.00Outperform
    Raymond James
    Erasca Inc.
    $ERAS
    11/18/2024$6.00Buy
    Jefferies
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $CHRO
    $ERAS
    $HLTH
    $INBS
    SEC Filings

    View All

    iSpecimen Inc. filed SEC Form 8-K: Other Events

    8-K - iSpecimen Inc. (0001558569) (Filer)

    2/18/26 4:30:19 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/12/26 8:55:44 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Intelligent Bio Solutions Inc.

    10-Q - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/12/26 8:31:15 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $CHRO
    $ERAS
    $HLTH
    $INBS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CHRO
    $ERAS
    $HLTH
    $INBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho resumed coverage on Erasca with a new price target

    Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

    1/27/26 8:45:40 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Erasca with a new price target

    Piper Sandler initiated coverage of Erasca with a rating of Overweight and set a new price target of $5.00

    1/7/26 9:10:17 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Erasca with a new price target

    Stifel initiated coverage of Erasca with a rating of Buy and set a new price target of $4.00

    10/16/25 8:25:25 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CHRO
    $ERAS
    $HLTH
    $INBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

    4 - Nexalin Technology, Inc. (0001527352) (Issuer)

    3/13/25 4:52:26 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Medical Officer Owens David bought $3,100 worth of shares (1,000 units at $3.10), increasing direct ownership by 0.65% to 155,793 units (SEC Form 4)

    4 - Nexalin Technology, Inc. (0001527352) (Issuer)

    2/5/25 3:17:26 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Medical Officer Owens David bought $2,980 worth of shares (1,000 units at $2.98), increasing direct ownership by 0.65% to 154,793 units (SEC Form 4)

    4 - Nexalin Technology, Inc. (0001527352) (Issuer)

    2/4/25 5:05:25 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CHRO
    $ERAS
    $HLTH
    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman & CEO Lim Jonathan E

    4 - Erasca, Inc. (0001761918) (Issuer)

    1/30/26 9:05:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and CBO Chacko David M. acquired $21,250 worth of shares (17,793 units at $1.19), increasing direct ownership by 7% to 279,980 units (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    1/30/26 9:04:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Morris Shannon

    4 - Erasca, Inc. (0001761918) (Issuer)

    1/30/26 9:02:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CHRO
    $ERAS
    $HLTH
    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Registration Momentum Builds Across the Oncology Pipeline

    VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The FDA's accelerated approval framework continues to deliver measurable population health gains, with a January 2026 analysis in Cancer Research Communications confirming that drugs cleared through the program improved real-world progression-free survival in 65% of solid tumor indications studied, with none performing worse than the existing standard of care[1]. That track record is fueling a concentrated push among clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types, as demonstrated by Oncolytics Biotech Inc. (NASDAQ:ONCY), Incyte (NASD

    2/17/26 10:48:02 AM ET
    $ACRV
    $ERAS
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete

    Live Production Marketplace Now AvailableWoburn, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ:ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone delivers a fully integrated, live marketplace that connects customer requests with supplier inventories, enabling streamlined operations, reduced costs, and a foundation for future growth.Chief Executive Officer Ms. Katie Field commented, "This Milestone 2 achievement demonstrates end-to-end system integration, legacy data migration, and activation of a production-ready Sale

    2/6/26 9:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CHRO
    $ERAS
    $HLTH
    $INBS
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies

    Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cart

    8/15/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $CHRO
    $ERAS
    $HLTH
    $INBS
    Leadership Updates

    Live Leadership Updates

    View All

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

    HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin's strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer's disease and Traumatic Brain Injury (TBI). In anticipation of the Company's new FDA submissions, Dr. Rothstein will support Nexalin's preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein bring

    10/13/25 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

    HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025. Mr. Van Fleet brings more than 20 years of experience in public accounting and assurance services, most recently serving as Partner at Marcum LLP (formerly Friedman LLP). In this role, he led the firm's assurance practice and advised both publicly traded and privately held clients across a wide range of sectors including technology, life sciences, manufacturing, and distribution. He

    8/1/25 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CHRO
    $ERAS
    $HLTH
    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care